Figure 1. Myeloid cells from LACC1 Val254 disease-risk carriers demonstrate decreased PRR-induced cytokine secretion.

Human MDMs (n=100) were treated for 24 h with (a) 1, 10 or 100 μg ml⁻¹ MDP, or (b) 1, 10 or 100 μg ml⁻¹ Pam₃Cys. (c) Human MDDCs (n=98) were treated for 24 h with 1 μg ml⁻¹ MDP (NOD2 ligand), 1 μg ml⁻¹ Pam₃Cys (TLR2 ligand), 0.01 μg ml⁻¹ lipid A (TLR4 ligand) or 0.5 ng ml⁻¹ flagellin (TLR5 ligand) for 24 h. Shown is fold IL-1β-secreted protein induction (log₂-transformed) upon PRR stimulation stratified on rs3764147 genotype. Error bars depict s.e.m. *P<0.05; **P<0.01; ***P<0.001; determined by 2-tailed t-test.